Several kinds of ICB monoclonal antibodies (mAbs) have been applied in preclinical models of cancer and in patients, targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) 2, programmed death 1 (PD-1), PD-1 ligand 1 (PD-L1) 3, transforming growth factor (TGF)-β 4, blocking immune checkpoints, and facilitating anti-tumor activity. This evidence concerns the gene CD274 and neoplasm.